Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study.

Lyu H, Zhao SS, Yoshida K, Tedeschi SK, Xu C, Nigwekar SU, Leder BZ, Solomon DH.

J Clin Endocrinol Metab. 2020 Jan 2. pii: dgz321. doi: 10.1210/clinem/dgz321. [Epub ahead of print]

PMID:
31894244
2.

Cardiovascular Calcifications Among Patients With Uremia: Answers to Hard Questions.

Nigwekar SU.

Adv Chronic Kidney Dis. 2019 Nov;26(6):407-408. doi: 10.1053/j.ackd.2019.11.001. No abstract available.

PMID:
31831118
3.

Kidney Function Decline among Black Patients with Sickle Cell Trait and Sickle Cell Disease: An Observational Cohort Study.

Olaniran KO, Allegretti AS, Zhao SH, Achebe MM, Eneanya ND, Thadhani RI, Nigwekar SU, Kalim S.

J Am Soc Nephrol. 2020 Feb;31(2):393-404. doi: 10.1681/ASN.2019050502. Epub 2019 Dec 6.

PMID:
31810990
4.

Validity of International Classification of Diseases Codes for Sickle Cell Trait and Sickle Cell Disease.

Olaniran KO, Seethapathy H, Zhao SH, Allegretti AS, Kalim S, Nigwekar SU.

J Gen Intern Med. 2019 Nov 19. doi: 10.1007/s11606-019-05555-w. [Epub ahead of print] No abstract available.

PMID:
31745854
5.

Impact of hemodialysis on the concentrations of sodium and potassium during infusion of sodium thiosulfate using an In Vitro hemodialysis model.

Nigwekar SU, Pai AB, Mueller B, Dean MC, Costello G, Sherman CR.

PLoS One. 2019 Nov 13;14(11):e0224767. doi: 10.1371/journal.pone.0224767. eCollection 2019.

6.

HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype.

Malhotra R, Mauer AC, Lino Cardenas CL, Guo X, Yao J, Zhang X, Wunderer F, Smith AV, Wong Q, Pechlivanis S, Hwang SJ, Wang J, Lu L, Nicholson CJ, Shelton G, Buswell MD, Barnes HJ, Sigurslid HH, Slocum C, Rourke CO, Rhee DK, Bagchi A, Nigwekar SU, Buys ES, Campbell CY, Harris T, Budoff M, Criqui MH, Rotter JI, Johnson AD, Song C, Franceschini N, Debette S, Hoffmann U, Kälsch H, Nöthen MM, Sigurdsson S, Freedman BI, Bowden DW, Jöckel KH, Moebus S, Erbel R, Feitosa MF, Gudnason V, Thanassoulis G, Zapol WM, Lindsay ME, Bloch DB, Post WS, O'Donnell CJ.

Nat Genet. 2019 Nov;51(11):1580-1587. doi: 10.1038/s41588-019-0514-8. Epub 2019 Oct 28.

PMID:
31659325
7.

Chronic prolonged hyponatremia and risk of hip fracture in elderly patients with chronic kidney disease.

Nigwekar SU, Negri AL, Bajpai D, Allegretti A, Kalim S, Seethapathy H, Bhan I, Murthy K, Ayus JC.

Bone. 2019 Oct;127:556-562. doi: 10.1016/j.bone.2019.07.029. Epub 2019 Jul 27.

PMID:
31362067
8.

Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.

Lyu H, Zhao SS, Yoshida K, Tedeschi SK, Xu C, Nigwekar SU, Leder BZ, Solomon DH.

J Clin Endocrinol Metab. 2019 Nov 1;104(11):5611-5620. doi: 10.1210/jc.2019-00924.

PMID:
31265071
9.

Correlation between clinical and pathological features of cutaneous calciphylaxis.

Dutta P, Chaudet KM, Nazarian RM, Kroshinsky D, Nigwekar SU.

PLoS One. 2019 Jun 13;14(6):e0218155. doi: 10.1371/journal.pone.0218155. eCollection 2019.

10.

Revisiting therapeutic options for calciphylaxis.

Seethapathy H, Nigwekar SU.

Curr Opin Nephrol Hypertens. 2019 Sep;28(5):448-454. doi: 10.1097/MNH.0000000000000520.

PMID:
31169527
11.

Blood Microbiome Profile in CKD : A Pilot Study.

Shah NB, Allegretti AS, Nigwekar SU, Kalim S, Zhao S, Lelouvier B, Servant F, Serena G, Thadhani RI, Raj DS, Fasano A.

Clin J Am Soc Nephrol. 2019 May 7;14(5):692-701. doi: 10.2215/CJN.12161018. Epub 2019 Apr 8.

PMID:
30962186
12.

Intervals between bone mineral density testing with dual-energy X-ray absorptiometry scans in clinical practice.

Lyu H, Yoshida K, Tedeschi SK, Zhao S, Xu C, Nigwekar SU, Leder BZ, Solomon DH.

Osteoporos Int. 2019 Apr;30(4):923-927. doi: 10.1007/s00198-019-04847-5. Epub 2019 Jan 24.

PMID:
30680429
13.

Medication Prescription Patterns for Secondary Hyperparathyroidism: More Questions than Answers.

Seethapathy H, Nigwekar SU.

Clin J Am Soc Nephrol. 2019 Feb 7;14(2):178-179. doi: 10.2215/CJN.15081218. Epub 2019 Jan 21. No abstract available.

14.

Demystifying the Benefits and Harms of Anticoagulation for Atrial Fibrillation in Chronic Kidney Disease.

Garlo KG, Steele DJR, Nigwekar SU, Chan KE.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):125-136. doi: 10.2215/CJN.06430518. Epub 2018 Dec 28.

15.

Calciphylaxis-as a drug induced adverse event.

Portales-Castillo I, Kroshinsky D, Malhotra CK, Culber-Costley R, Cozzolino MG, Karparis S, Halasz CL, Goverman J, Manley HJ, Malhotra R, Nigwekar SU.

Expert Opin Drug Saf. 2019 Jan;18(1):29-35. doi: 10.1080/14740338.2019.1559813. Epub 2018 Dec 24. Review.

PMID:
30574812
16.

Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.

Lyu H, Jundi B, Xu C, Tedeschi SK, Yoshida K, Zhao S, Nigwekar SU, Leder BZ, Solomon DH.

J Clin Endocrinol Metab. 2019 May 1;104(5):1753-1765. doi: 10.1210/jc.2018-02236.

17.

Sickle Cell Nephropathy in the Pediatric Population.

Olaniran KO, Eneanya ND, Nigwekar SU, Vela-Parada XF, Achebe MM, Sharma A, Thadhani RI.

Blood Purif. 2019;47(1-3):205-213. doi: 10.1159/000494581. Epub 2018 Dec 5. Review.

18.

Palliative Care Use and Patterns of End-of-Life Care in Hospitalized Patients With Calciphylaxis.

Olaniran KO, Percy SG, Zhao S, Blais C, Jackson V, Kamdar MM, Goverman J, Kroshinsky D, Temel JS, Nigwekar SU, Eneanya ND.

J Pain Symptom Manage. 2019 Feb;57(2):e1-e3. doi: 10.1016/j.jpainsymman.2018.10.514. Epub 2018 Nov 3. No abstract available.

19.

Long-Term Anticoagulation for Patients Receiving Dialysis.

Nigwekar SU, Thadhani R.

Circulation. 2018 Oct 9;138(15):1530-1533. doi: 10.1161/CIRCULATIONAHA.118.037091. No abstract available.

PMID:
30354526
20.

Review: update on the management of calciphylaxis.

Seethapathy H, Brandenburg VM, Sinha S, El-Azhary RA, Nigwekar SU.

QJM. 2019 Jan 1;112(1):29-34. doi: 10.1093/qjmed/hcy234. Review.

PMID:
30304522
21.

Factors associated with false-negative pathologic diagnosis of calciphylaxis.

Williams EA, Moy AP, Cipriani NA, Nigwekar SU, Nazarian RM.

J Cutan Pathol. 2019 Jan;46(1):16-25. doi: 10.1111/cup.13364. Epub 2018 Nov 4.

PMID:
30280393
22.

The Successful Use of Apixaban in Dialysis Patients with Calciphylaxis Who Require Anticoagulation: A Retrospective Analysis.

Garza-Mayers AC, Shah R, Sykes DB, Nigwekar SU, Kroshinsky D.

Am J Nephrol. 2018;48(3):168-171. doi: 10.1159/000491881. Epub 2018 Sep 3.

PMID:
30176675
23.

Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis.

Allegretti AS, Vela Parada X, Ortiz GA, Long J, Krinsky S, Zhao S, Fuchs BC, Sojoodi M, Zhang D, Karumanchi SA, Kalim S, Nigwekar SU, Thadhani RI, Parikh SM, Chung RT.

Hepatology. 2019 Feb;69(2):729-741. doi: 10.1002/hep.30230. Epub 2019 Jan 4.

24.

Calciphylaxis in Patients With Normal Renal Function: A Case Series and Systematic Review.

Bajaj R, Courbebaisse M, Kroshinsky D, Thadhani RI, Nigwekar SU.

Mayo Clin Proc. 2018 Sep;93(9):1202-1212. doi: 10.1016/j.mayocp.2018.06.001. Epub 2018 Jul 27.

PMID:
30060958
25.

Calciphylaxis.

Nigwekar SU, Thadhani R, Brandenburg VM.

N Engl J Med. 2018 Jul 26;379(4):399-400. doi: 10.1056/NEJMc1807324. No abstract available.

PMID:
30044942
26.

Cutaneous calcification in patients with kidney disease is not always calciphylaxis.

Nigwekar SU, Nazarian RM.

Kidney Int. 2018 Aug;94(2):244-246. doi: 10.1016/j.kint.2018.04.019.

PMID:
30031445
27.

Calciphylaxis.

Nigwekar SU, Thadhani R, Brandenburg VM.

N Engl J Med. 2018 May 3;378(18):1704-1714. doi: 10.1056/NEJMra1505292. Review. No abstract available.

PMID:
29719190
28.

Urinary Stone Disease and Cardiovascular Disease Risk in a Rural Chinese Population.

Fan X, Kalim S, Ye W, Zhao S, Ma J, Nigwekar SU, Chan KE, Cui J, Cai J, Wang L, Heng W, Zhou Y, Sun Y, Cui R, Zhang W, Wang B, Dai Q, Li X, Thadhani R, Li X.

Kidney Int Rep. 2017 Jun 8;2(6):1042-1049. doi: 10.1016/j.ekir.2017.06.001. eCollection 2017 Nov.

29.

Malnutrition-inflammation is a risk factor for cerebral small vessel diseases and cognitive decline in peritoneal dialysis patients: a cross-sectional observational study.

Zheng K, Wang H, Hou B, You H, Yuan J, Luo K, Chen L, Li M, Xu Q, Zhu Y, Cui L, Nigwekar SU, Feng F, Li X.

BMC Nephrol. 2017 Dec 20;18(1):366. doi: 10.1186/s12882-017-0777-1.

30.

Location of skin lesions in Henoch-Schönlein purpura and its association with significant renal involvement.

St John J, Vedak P, Garza-Mayers AC, Hoang MP, Nigwekar SU, Kroshinsky D.

J Am Acad Dermatol. 2018 Jan;78(1):115-120. doi: 10.1016/j.jaad.2017.04.1122.

PMID:
29241772
31.

Increased Bone Morphogenetic Protein Signaling in the Cutaneous Vasculature of Patients with Calciphylaxis.

Nigwekar SU, Jiramongkolchai P, Wunderer F, Bloch E, Ichinose R, Nazarian RM, Thadhani RI, Malhotra R, Bloch DB.

Am J Nephrol. 2017;46(5):429-438. doi: 10.1159/000484418. Epub 2017 Nov 9.

32.

The prevalence and mortality of hyponatremia is seriously underestimated in Chinese general medical patients: an observational retrospective study.

Hao J, Li Y, Zhang X, Pang C, Wang Y, Nigwekar SU, Qiu L, Chen L.

BMC Nephrol. 2017 Oct 31;18(1):328. doi: 10.1186/s12882-017-0744-x.

33.

Characterization and Correction of Olfactory Deficits in Kidney Disease.

Nigwekar SU, Weiser JM, Kalim S, Xu D, Wibecan JL, Dougherty SM, Mercier-Lafond L, Corapi KM, Eneanya ND, Holbrook EH, Brown D, Thadhani RI, Păunescu TG.

J Am Soc Nephrol. 2017 Nov;28(11):3395-3403. doi: 10.1681/ASN.2016121308. Epub 2017 Aug 3.

34.

Effectiveness of self-management support in maintenance haemodialysis patients with hypertension: A pilot cluster randomized controlled trial.

Huang B, Li Z, Wang Y, Xia J, Shi T, Jiang J, Nolan MT, Li X, Nigwekar SU, Chen L.

Nephrology (Carlton). 2018 Aug;23(8):755-763. doi: 10.1111/nep.13098.

PMID:
28666310
35.

Calciphylaxis.

Nigwekar SU.

Curr Opin Nephrol Hypertens. 2017 Jul;26(4):276-281. doi: 10.1097/MNH.0000000000000328. Review.

36.

Vitamin K-Dependent Carboxylation of Matrix Gla Protein Influences the Risk of Calciphylaxis.

Nigwekar SU, Bloch DB, Nazarian RM, Vermeer C, Booth SL, Xu D, Thadhani RI, Malhotra R.

J Am Soc Nephrol. 2017 Jun;28(6):1717-1722. doi: 10.1681/ASN.2016060651. Epub 2017 Jan 3.

37.

A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors.

Nigwekar SU, Zhao S, Wenger J, Hymes JL, Maddux FW, Thadhani RI, Chan KE.

J Am Soc Nephrol. 2016 Nov;27(11):3421-3429. Epub 2016 Apr 14.

38.

Calciphylaxis in peritoneal dialysis patients: a single center cohort study.

Zhang Y, Corapi KM, Luongo M, Thadhani R, Nigwekar SU.

Int J Nephrol Renovasc Dis. 2016 Sep 19;9:235-241. eCollection 2016.

39.

Interventions for lowering plasma homocysteine levels in dialysis patients.

Nigwekar SU, Kang A, Zoungas S, Cass A, Gallagher MP, Kulshrestha S, Navaneethan SD, Perkovic V, Strippoli GF, Jardine MJ.

Cochrane Database Syst Rev. 2016 May 31;(5):CD004683. doi: 10.1002/14651858.CD004683.pub4. Review.

PMID:
27243372
40.

Mild prolonged chronic hyponatremia and risk of hip fracture in the elderly.

Ayus JC, Fuentes NA, Negri AL, Moritz ML, Giunta DH, Kalantar-Zadeh K, Nigwekar SU, Thadhani RI, Go AS, De Quiros FG.

Nephrol Dial Transplant. 2016 Oct;31(10):1662-9. doi: 10.1093/ndt/gfw029. Epub 2016 Mar 23.

PMID:
27190372
41.

We Do Too Many Parathyroidectomies for Calciphylaxis.

Nigwekar SU, Sprague SM.

Semin Dial. 2016 Jul;29(4):312-4. doi: 10.1111/sdi.12502. Epub 2016 Apr 15.

PMID:
27082830
42.

Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease.

Lundquist AL, Nigwekar SU.

Curr Opin Nephrol Hypertens. 2016 Mar;25(2):120-6. doi: 10.1097/MNH.0000000000000203. Review.

43.

The Role of Bone Scintigraphy in the Diagnosis of Calciphylaxis.

Paul S, Rabito CA, Vedak P, Nigwekar SU, Kroshinsky D.

JAMA Dermatol. 2017 Jan 1;153(1):101-103. doi: 10.1001/jamadermatol.2015.4591. No abstract available.

PMID:
26677101
44.

Multidisciplinary approach to calcific uremic arteriolopathy.

Nigwekar SU.

Curr Opin Nephrol Hypertens. 2015 Nov;24(6):531-7. doi: 10.1097/MNH.0000000000000175. Review.

PMID:
26371529
45.

Raman spectroscopy for label-free identification of calciphylaxis.

Lloyd WR, Agarwal S, Nigwekar SU, Esmonde-White K, Loder S, Fagan S, Goverman J, Olsen BR, Jumlongras D, Morris MD, Levi B.

J Biomed Opt. 2015 Aug;20(8):80501. doi: 10.1117/1.JBO.20.8.080501.

46.

Calciphylaxis: risk factors, diagnosis, and treatment.

Nigwekar SU, Kroshinsky D, Nazarian RM, Goverman J, Malhotra R, Jackson VA, Kamdar MM, Steele DJ, Thadhani RI.

Am J Kidney Dis. 2015 Jul;66(1):133-46. doi: 10.1053/j.ajkd.2015.01.034. Epub 2015 May 7. Review.

47.

Interventions for lowering plasma homocysteine levels in kidney transplant recipients.

Kang A, Nigwekar SU, Perkovic V, Kulshrestha S, Zoungas S, Navaneethan SD, Cass A, Gallagher MP, Ninomiya T, Strippoli GF, Jardine MJ.

Cochrane Database Syst Rev. 2015 May 4;(5):CD007910. doi: 10.1002/14651858.CD007910.pub2. Review.

PMID:
25938479
48.

Nutritional vitamin D supplementation in dialysis: a randomized trial.

Bhan I, Dobens D, Tamez H, Deferio JJ, Li YC, Warren HS, Ankers E, Wenger J, Tucker JK, Trottier C, Pathan F, Kalim S, Nigwekar SU, Thadhani R.

Clin J Am Soc Nephrol. 2015 Apr 7;10(4):611-9. doi: 10.2215/CJN.06910714. Epub 2015 Mar 13.

49.

Quantifying a rare disease in administrative data: the example of calciphylaxis.

Nigwekar SU, Solid CA, Ankers E, Malhotra R, Eggert W, Turchin A, Thadhani RI, Herzog CA.

J Gen Intern Med. 2014 Aug;29 Suppl 3:S724-31. doi: 10.1007/s11606-014-2910-1.

50.

Vitamin D receptor activation: cardiovascular and renal implications.

Nigwekar SU, Thadhani R.

Kidney Int Suppl (2011). 2013 Dec;3(5):427-430. Review.

Supplemental Content

Loading ...
Support Center